Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. It offers Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. The company was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.

Nyxoah S.A.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

INSIDE INFORMATION REGULATED INFORMATION NYXOAH SECURES FINANCING COMMITMENTS OF UP TO U.S. $77 MILLION TO DRIVE U.S. COMMERCIALIZATION OF GENIO FINANCINGS ARE COMPRISED OF EQUITY INVESTMENTS, INCLUDING FROM COCHLEAR, RESMED AND NYXOAH'S CHAIRMAN AND MANAGEMENT, AND A CONVERTIBLE BOND. MONT-SAINT-GUIBERT, BELGIUM  NOVEMBER 13, 2025, 2025, 10:11PM CET / 4:11 PM ET  NYXOAH SA (EURONEXT BRUSSELS/NASDAQ: NYXH) (NYXOAH OR THE COMPANY), A MEDICAL TECHNOLOGY COMPANY FOCUSED ON THE DEVELOPMENT AND COMMERCIALIZATION OF INNOVATIVE SOLUTIONS TO TREAT OBSTRUCTIVE SLEEP APNEA (OSA) THROUGH NEUROMODULATION, TODAY ANNOUNCED A 22 MILLION PRIVATE PLACEMENT OF EQUITY, A U.S. $5.6 MILLION REGISTERED DIRECT OFFERING, AND A 17 MILLION REGISTERED DIRECT OFFERING COMBINED WITH A CONVERTIBLE BOND FINANCING OF UP TO 45 MILLION.

NYXOAH SECURES FINANCING COMMITMENTS OF UP TO U.S. $77 MILLION TO DRIVE U.S. COMMERCIALIZATION OF GENIO

REGULATED INFORMATION NYXOAH REPORTS THIRD QUARTER 2025 FINANCIAL AND OPERATING RESULTS US LAUNCH OFF TO A STRONG START. FIRST COMMERCIAL GENIO IMPLANTS COMPLETED WITH WIDESPREAD PAYER COVERAGE DRIVES INITIAL REVENUE.

NYXOAH REPORTS THIRD QUARTER 2025 FINANCIAL AND OPERATING RESULTS

NYXOAH TO PARTICIPATE IN THE STIFEL 2025 HEALTHCARE CONFERENCE MONT-SAINT-GUIBERT, BELGIUM  NOVEMBER 3, 10:05PM CET / 4:05PM ET  NYXOAH SA (EURONEXT BRUSSELS/NASDAQ: NYXH), A MEDICAL TECHNOLOGY COMPANY THAT DEVELOPS BREAKTHROUGH TREATMENT ALTERNATIVES FOR OBSTRUCTIVE SLEEP APNEA (OSA), TODAY ANNOUNCED THAT THE COMPANY WILL PARTICIPATE IN THE STIFEL 2025 HEALTHCARE CONFERENCE ON TUESDAY, NOV. 11, 2025. THE COMPANY IS SCHEDULED TO PRESENT AT 9:20AM EASTERN TIME THE SAME DAY VIA WEBCAST.

NYXOAH TO PARTICIPATE IN THE STIFEL 2025 HEALTHCARE CONFERENCE

NYXOAH TO RELEASE THIRD QUARTER 2025 FINANCIAL RESULTS ON NOVEMBER 13, 2025

NYXOAH ANNOUNCES FIRST U.S. COMMERCIAL PATIENTS IMPLANTED WITH GENIO SYSTEM EARLY COMMERCIAL LAUNCH DEMONSTRATES STRONG PHYSICIAN DEMAND, SUCCESSFUL PRE-AUTHORIZATIONS, AND WIDESPREAD PAYOR COVERAGE MONT-SAINT-GUIBERT, BELGIUM  OCTOBER 6, 2025 7:00 CET / 1:00 ET  NYXOAH SA (EURONEXT BRUSSELS/NASDAQ: NYXH), A MEDICAL TECHNOLOGY COMPANY THAT DEVELOPS BREAKTHROUGH TREATMENT ALTERNATIVES FOR OBSTRUCTIVE SLEEP APNEA (OSA), TODAY ANNOUNCED THAT THE FIRST U.S. COMMERCIAL PATIENTS HAVE BEEN SUCCESSFULLY IMPLANTED WITH THE GENIO SYSTEM FOLLOWING FDA APPROVAL. "WE ARE THRILLED TO ANNOUNCE THAT THE FIRST COMMERCIAL PATIENTS HAVE NOW RECEIVED GENIO IMPLANTS, MARKING A SIGNIFICANT MILESTONE IN BRINGING THIS INNOVATIVE THERAPY TO OSA PATIENTS IN THE U.S.," SAID OLIVIER TAELMAN, CHIEF EXECUTIVE OFFICER.

NYXOAH ANNOUNCES FIRST U.S. COMMERCIAL PATIENTS IMPLANTED WITH GENIO SYSTEM

REGULATED INFORMATION PUBLICATION RELATING TO TRANSPARENCY NOTIFICATIONS MONT-SAINT-GUIBERT (BELGIUM), OCTOBER 3, 2025 , 10:30 PM CET / 4:30 PM ET  IN ACCORDANCE WITH ARTICLE14 OF THE ACT OF 2 MAY 2007 ON THE DISCLOSURE OF LARGE SHAREHOLDINGS, NYXOAH SA (EURONEXT BRUSSELS/NASDAQ: NYXH) ANNOUNCES THAT IT RECEIVED A TRANSPARENCY NOTIFICATION AS DETAILED BELOW. VESTAL POINT CAPITAL ON OCTOBER 1, 2025, NYXOAH RECEIVED A TRANSPARENCY NOTIFICATION FROM VESTAL POINT CAPITAL FOLLOWING AN ACQUISITION OR DISPOSAL OF VOTING SECURITIES OR VOTING RIGHTS.

PUBLICATION RELATING TO TRANSPARENCY NOTIFICATIONS

NYXOAH PROVIDES AN UPDATE ON EXPANDED MIDDLE EAST PRESENCE NEW CENTERS IN DUBAI, KUWAIT, AND ABU DHABI FOLLOWING FIRST GENIO IMPLANT IN THE REGION EARLIER IN 2025 MONT-SAINT-GUIBERT, BELGIUM  SEPTEMBER 23, 2025, 10:10PM CET / 4:10PM ET  NYXOAH SA (EURONEXT BRUSSELS/NASDAQ: NYXH), A MEDICAL TECHNOLOGY COMPANY THAT DEVELOPS BREAKTHROUGH TREATMENT ALTERNATIVES FOR OBSTRUCTIVE SLEEP APNEA (OSA), TODAY ANNOUNCED THE CONTINUED EXPANSION OF ITS COMMERCIAL FOOTPRINT IN THE MIDDLE EAST, FOLLOWING THE FIRST SUCCESSFUL GENIO IMPLANT IN ABU DHABI IN SEPTEMBER 2025. THE MIDDLE EAST IS HOME TO WORLD-CLASS HEALTHCARE SYSTEMS, RENOWNED KEY OPINION LEADERS, AND CENTERS OF EXCELLENCE WITH OUTSTANDING FACILITIES.

Nyxoah S.A.

NYXH

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Nyxoah S.A.

NYXH.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

NYXH